108 related articles for article (PubMed ID: 31134644)
1. Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer: Insight into the survival paradox.
Kim HS; Kim KM; Lee SB; Kim GR; Han YD; Cho MS; Hur H; Lee KY; Kim NK; Min BS
J Surg Oncol; 2019 Sep; 120(3):423-430. PubMed ID: 31134644
[TBL] [Abstract][Full Text] [Related]
2. Survival paradox between stage IIB/C and stage IIIA colon cancer: is it time to revise the American Joint Committee on Cancer TNM system?
Chu QD; Li T; Hsieh MC; Yi Y; Gibbs JF; Sahawneh J; Sang W; Gallagher J; Wu XC
Surg Endosc; 2024 May; 38(5):2857-2870. PubMed ID: 38575828
[TBL] [Abstract][Full Text] [Related]
3. Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy.
Chu QD; Zhou M; Medeiros KL; Peddi P; Kavanaugh M; Wu XC
BMC Cancer; 2016 Jul; 16():460. PubMed ID: 27412163
[TBL] [Abstract][Full Text] [Related]
4. Positive surgical margins contribute to the survival paradox between patients with stage IIB/C (T4N0) and stage IIIA (T1-2N1, T1N2a) colon cancer.
Chu QD; Zhou M; Medeiros K; Peddi P
Surgery; 2016 Nov; 160(5):1333-1343. PubMed ID: 27425043
[TBL] [Abstract][Full Text] [Related]
5. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
6. Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer.
Li H; Fu G; Wei W; Huang Y; Wang Z; Liang T; Tian S; Chen H; Zhang W
Front Oncol; 2020; 10():595107. PubMed ID: 33312954
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis.
Tian M; Zhou Z
Transl Cancer Res; 2022 Dec; 11(12):4241-4253. PubMed ID: 36644182
[TBL] [Abstract][Full Text] [Related]
8. Survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer.
Kim MJ; Jeong SY; Choi SJ; Ryoo SB; Park JW; Park KJ; Oh JH; Kang SB; Park HC; Heo SC; Park JG
Ann Surg Oncol; 2015 Feb; 22(2):505-12. PubMed ID: 25145501
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
13. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.
Netter J; Lehmann-Che J; Lambert J; Tallet A; Lourenco N; Soliman H; Bertheau P; Pariente B; Chirica M; Pocard M; Allez M; De The H; Gornet JM
Bull Cancer; 2015 Feb; 102(2):117-25. PubMed ID: 25609485
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
Chouhan H; Sammour T; L Thomas M; W Moore J
Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
[TBL] [Abstract][Full Text] [Related]
15. A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations.
Metz AJ; Bourke MJ; Moss A; Dower A; Zarzour P; Hawkins NJ; Ward RL; Hesson LB
Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):319-26. PubMed ID: 23354161
[TBL] [Abstract][Full Text] [Related]
16. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
